ACS CAN wages state-by-state battle to expand access to biomarker testing – The Cancer Letter

With growing evidence that molecular characterization of a tumor helps predict a patient’s prognosis and response to specific treatments, biomarker testing has been required or recommended for more than half of the 62 oncology drugs introduced over the past five years. However, health insurance policies don’t always cover tests, thus denying their clients access to […]

Read the full article here

Related Articles